Alembic Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
APLLTD · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Alembic Pharmaceuticals has informed the stock exchanges that the trading window for dealing in its securities will remain closed from 1st October 2025 until 48 hours after the declaration of its unaudited financial results for the quarter and half year ended 30th September 2025. This closure is being carried out as per the company's internal code of conduct framed under SEBI's Prohibition of Insider Trading Regulations, 2015, and applies to designated persons and their immediate relatives. The exact date of the board meeting to approve the Q2 and H1 FY26 financial results has not yet been announced and will be communicated separately. The intimation was signed by Manisha Saraf, Company Secretary, and is addressed to both BSE and NSE.
This is a routine regulatory compliance filing and does not, by itself, indicate any positive or negative news. However, it signals that the company's Q2 FY26 earnings announcement is approaching, which investors should watch for upcoming revenue, profit, and margin updates.